Sub-Q Bionics Company Showcase | MedTech World Middle East 2026

Why It Matters

The solution tackles a massive, underserved lymphedema market, promising to lower complications, healthcare utilization, and improve quality of life for breast‑cancer survivors.

Key Takeaways

• Lymphedema affects up to 65% of breast cancer survivors.
• Bionic lymph node continuously drains fluid via implantable pump.
• AI‑enabled cloud analytics monitor therapy and predict complications.
• Class III PMA pathway targets Breakthrough Device designation.
• $1.1M pre‑seed raised; $3M seed round ongoing.

Pulse Analysis

Lymphedema remains one of the most persistent complications after breast cancer treatment, affecting as many as two‑thirds of survivors. Current standards rely on lifelong compression garments, manual lymphatic drainage, and intermittent decongestive therapy, which are cumbersome and often lead to skin infections, frequent emergency visits, and reduced mobility. The chronic nature of the disease creates a sizable economic burden, with annual costs estimated in the billions worldwide. This unmet clinical need has spurred interest in device‑based interventions that can restore physiological lymph flow without constant patient effort.

Sub‑Q Bionics’ bionic lymph node represents a convergence of micro‑engineering, fluid dynamics, and digital health. The implant’s microporous matrix mimics natural lymphatic architecture while an integrated micro‑pump provides continuous, low‑pressure drainage. Real‑time data streams to a secure cloud platform where AI algorithms analyze fluid volumes, pressure trends, and patient activity to adjust therapy parameters automatically. Early pre‑clinical studies demonstrated safe, sustained drainage, and the first human implantation reported no adverse events and a marked reduction in limb volume. By pursuing a Class III Premarket Approval pathway and seeking Breakthrough Device designation, Sub‑Q aims to accelerate regulatory clearance while positioning the product for favorable CMS reimbursement.

The market opportunity is compelling: over 15 million women globally live with lymphedema, many of whom experience recurrent infections and hospitalizations. A device that eliminates compression garments could capture a multi‑billion‑dollar segment, especially as payers prioritize solutions that reduce readmissions. Sub‑Q’s recent $1.1 million pre‑seed raise and ongoing $3 million seed round signal strong investor confidence in both the technology and its commercial potential. If successful, the bionic lymph node could set a new standard of care, drive downstream innovations in implantable fluid‑management systems, and reshape the economics of post‑cancer survivorship care.

Original Description

At MedTech World Middle East 2026, Jordan Pollack, Co-Founder & CEO of Sub-Q Bionics, introduces a new approach to treating lymphedema, a chronic and progressive condition affecting up to 65% of breast cancer survivors.

A biomedical engineer trained at the University of Michigan and former Boston Scientific R&D leader, Jordan shares his journey from developing vascular devices to building Sub-Q Bionics, a company focused on restoring freedom and mobility to women living with lymphedema.

Sub-Q Bionics is developing a “bionic lymph node”, a microporous implantable device with an integrated pump system that continuously drains excess lymphatic fluid. The system connects to a cloud-based platform with AI-enabled analytics, aiming to eliminate the need for lifelong compression garments and reduce infections, ER visits, and hospitalizations.

In this showcase, Jordan covers:

The unmet need in lymphedema care

Clinical progress, including preclinical studies and an initial human case

Regulatory strategy as a Class III PMA device

CMS reimbursement pathway and Breakthrough Device potential

Market opportunity in a significantly underserved patient population

The company’s recent $1.1M pre-seed raise and ongoing $3M seed round

With an experienced leadership team, advisory board of leading surgeons, and active patient advocacy involvement, Sub-Q Bionics is building more than a device; it’s building a long-term solution.

Subscribe to our channel for more insights from global MedTech leaders, startup showcases, investor perspectives, and exclusive summit highlights.

#MedTechWorld #MTWMiddleEast2026 #HealthcareInnovation #Lymphedema #BreastCancerSurvivors #HealthTech #MedicalDevices #StartupShowcase #DigitalHealth #Biotech #HealthcareStartups #MedTechInvesting